1. Genotypic characterization of 'inferred' rifampin mutations in GenoType MTBDRplus assay and its association with phenotypic susceptibility testing of Mycobacterium tuberculosis.
- Author
-
Singhal R, Anthwal D, Kumar G, Sah G, Salfinger M, Choudhury S, Arora J, Bhalla M, Myneedu VP, Sarin R, and Haldar S
- Subjects
- Bacterial Proteins genetics, DNA-Directed RNA Polymerases genetics, Genotype, Humans, Microbial Sensitivity Tests, Phenotype, Sputum microbiology, Tuberculosis microbiology, Antitubercular Agents pharmacology, Drug Resistance, Multiple, Bacterial genetics, Mutation, Mycobacterium tuberculosis drug effects, Rifampin pharmacology
- Abstract
In GenoType MTBDRplus assay [line probe assay (LPA)], when Mycobacterium tuberculosis (M. tuberculosis) sample DNA fails to hybridize to at least 1 rpoB wild-type probe and any mutation probe, it is inferred as rifampin (RIF)-resistant. In this study, we sought to identify such 'inferred' mutations in M. tuberculosis isolates (n = 203) by rpoB gene sequencing and determined their association with phenotypic resistance. D516Y, H526N, L511P mutations were associated with both phenotypically sensitive (59%, n = 38/64) and resistant (23.7%, n = 33/139) antimicrobial susceptibility testing (AST) results, whereas S531W mutation was associated with only RIF-resistant isolates (33%, n = 46/139). These results demonstrated that, at standard drug concentrations, some 'inferred' mutations may be missed by RIF-AST (phenotypically sensitive). The use of LPA permits identification of these RIF-resistant isolates, and incorporation of additional mutation probes (e.g., S531W) could further increase LPA specificity. Further studies are needed to establish the significance of the type of 'inferred' mutation with clinical/treatment outcomes., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF